Literature DB >> 7042080

Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.

E L White, S C Shaddix, R W Brockman, L L Bennett.   

Abstract

9-beta-D-Arabinofuranosyl-2-fluoroadenine (2-F-ara-A), a derivative of 9-beta-D-arabinofuranosyladenine (ara-A) that is resistant to deamination, selectively inhibits DNA synthesis and has activity against mouse leukemia L1210 comparable to that of ara-A plus the adenosine deaminase inhibitor, 2'-deoxycoformycin. To determine if these two nucleosides have similar modes of action, comparisons were made of their effects and those of their triphosphates on enzymes known to be inhibited by ara-A or 9-beta-D-arabinofuranosyladenine 5'-triphosphate. 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-triphosphate was more effective than 9-beta-D-arabinofuranosyladenine 5'-triphosphate in inhibiting the reduction of adenosine 5'-diphosphate and cytidine 5'-diphosphate by ribonucleotide reductase from HEp-2 cells or L1210 cells. DNA polymerase alpha from L1210 cells was equally sensitive to 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate and 9-beta-D-arabinofuranosyladenine 5'-triphosphate, and DNA polymerase beta from L1210 cells was much less sensitive to both triphosphates. S-Adenosylhomocysteine hydrolase from L1210 cells was inactivated by 2-F-ara-A and ara-A, but higher concentrations of the fluoro derivative were required. These results are consistent with 2-F-ara-A and ara-A inhibition of DNA synthesis by inhibition of ribonucleotide reductase and DNA polymerase alpha.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7042080

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine.

Authors:  A A Adjei; L Dagnino; M M Wong; A R Paterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.

Authors:  Nobuyuki Yoshio; Yasukazu Kawai; Hiroki Hori; Takanori Ueda
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 3.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.

Authors:  V Gandhi; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Ocular toxicity of fludarabine: a purine analog.

Authors:  Xiaoyan Ding; Alexandra A Herzlich; Rachel Bishop; Jingsheng Tuo; Chi-Chao Chan
Journal:  Expert Rev Ophthalmol       Date:  2008-02

Review 7.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

8.  Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats.

Authors:  M Qian; X Wang; K Shanmuganathan; C K Chu; J M Gallo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

Authors:  L Danhauser; W Plunkett; M Keating; F Cabanillas
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.